For years, we’ve been hearing the same promise: biosimilars are coming to drive down the astronomical prices of biologic drugs. The logic seemed simple. Biologics are only a tiny slice of all prescriptions, yet they eat up more than half of the country’s drug budget. Biosimilars were supposed to be the new generics, creating competition and finally making these life-changing medicines more affordable.
But that’s not what happened. Not really.
Sure, biosimilars are on the market, and some doctors are prescribing them. But their impact has been a drop in the bucket compared to the tidal wave of savings everyone was hoping for. The problem isn’t the science behind them. The real question is why the market itself is broken.
It turns out it’s not just one roadblock. It’s a multi-car pileup.
Buried in Lawsuits
The first obstacle pops up long before a single patient gets a dose. It starts in a courtroom.
Big drug companies have gotten very good at building “patent thickets”—a dense jungle of patents covering not just the drug itself, but everything from its manufacturing process to the device that delivers it. Challenging this tangled mess, even when some patents are flimsy, can cost millions of dollars and drag on for years.
The outcome is exactly what you’d expect. A biosimilar can get the green light from regulators and still be stuck in legal limbo, unable to launch.
Just look at adalimumab (the main ingredient in Humira). Biosimilar versions were approved years before they could actually be sold in the U.S. because of legal battles. This sends a chilling message to any company thinking about making a biosimilar: get your lawyers and a giant checkbook ready.
The Bizarre World of Rebates
Even if a biosimilar survives the legal gauntlet and makes it to market, it runs straight into another wall: the rebate system.
Here’s how it works: insurers and their middlemen get huge kickbacks from brand-name drug makers. These rebates can make the original, super-expensive biologic the more profitable choice for the insurer, even if a biosimilar has a much lower sticker price.
So, a more expensive drug can end up being the “preferred” option.
If that sounds completely backward, it’s because it is. But that’s the system we have.
Old Habits Die Hard
Then there’s the human element. Doctors get comfortable with the drugs they know and trust. If a patient is stable and doing well on a biologic they’ve used for years, why rock the boat? The motivation to switch is low, especially since the cost savings don’t land in the doctor’s pocket.
There’s also a nagging perception problem. Despite having to prove they’re just as safe and effective, biosimilars are still viewed by some doctors and patients as “not quite the same.”
It’s a hurdle Europe cleared years ago, but the U.S. is still struggling to get over it.
These Aren’t Your Average Generics
It’s also important to remember that biosimilars and generics are two totally different animals.
A generic pill is simple to copy and cheap to make, which is why it can be 90% cheaper than the original. But biosimilars are large, complex molecules grown in living cells. Developing and manufacturing them is incredibly difficult and can cost hundreds of millions of dollars.
Because of that, the discounts are much smaller—think 20-40% off, not 90%. And for many in the healthcare system, that smaller price drop just isn’t a big enough carrot to get them to change.
A Maze of Red Tape
On top of everything else, the approval process itself has been a beast.
Historically, getting a biosimilar approved required a mountain of complex and expensive clinical trials. While regulators are starting to streamline things to encourage competition, it’s a step in the right direction that doesn’t fix the much bigger, systemic problems.
So, Is There Any Hope?
The good news is, yes, this mess can be fixed. But it means we have to stop tinkering around the edges and actually fix the broken incentives baked into our healthcare system.
What would that look like? For starters, we need to stop drug companies from building impenetrable patent walls just to block competition. The bizarre rebate system needs a complete overhaul so that the lowest-priced drug is actually the most attractive option. We also need to make it easier for pharmacists to substitute a biosimilar for a brand-name biologic, just like they do with generics, and do a much better job of educating doctors and patients to build the confidence that Europe has already achieved.
It’s All About the Incentives
At the end of the day, the biggest thing holding biosimilars back has nothing to do with the science. It’s all about the money.
Our current system is structured so that manufacturers, insurers, and their middlemen often make more money when drug prices are high. As long as that’s true, real competition will always be fighting an uphill battle.
Until we change those fundamental incentives, biosimilars will remain stuck in a weird limbo—a great idea in theory, but not the game-changer we were promised.
And for the patients who need these drugs, that’s more than a missed opportunity; it’s a massive failure.
